Skip to main content
Erschienen in: Clinical Rheumatology 9/2016

14.06.2016 | Original Article

Discrepancies in how the impact of gout is assessed in outcomes research compared to how health professionals view the impact of gout, using the lens of the International Classification of Functioning, Health and Disability (ICF)

verfasst von: Eveline M. Kool, Marieke J. Nijsten, Annelies E. van Ede, Tim L. Jansen, William J. Taylor

Erschienen in: Clinical Rheumatology | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

The International Classification of Functioning, Disability and Health (ICF) provides a common language to understand what health means. An ICF core set, a list of ICF categories affected by a certain disease, is useful to objectify the content validity of a health status measurement. This study aims to identify the potential items of a gout specific ‘ICF core set’. A three-round Delphi exercise was conducted, using web-based questionnaires. Health professionals, specialized in gout, nominated and subsequently rated the relevance of life areas divided into ICF categories. Agreement was determined by using the UCLA/RAND criteria. Simultaneously, a systematic review of gout measure outcomes was conducted. The results of these studies were compared using the second level of the ICF categories. In the Delphi study, consensus was found for 136 relevant ICF categories. The literature study extracted 134 different ICF categories in 149 articles. Three hundred and ten were non-defined outcomes. A large number of ICF categories were deemed to be relevant for people with gout. Only 29.7 % (19/64) of the level 2 categories, deemed to be relevant by health professionals, had been assessed as relevant in at least 5 % of gout outcome studies. Conversely, 70 % (19/27) of level 2 ICF categories assessed in at least 5 % of outcome studies were deemed relevant by health professionals. These ICF codes, which are found relevant in both studies, should be considered as mandatory in further research to a validated and practical core set of ICF categories. Published gout outcomes research fails to evaluate many life areas that are thought relevant by health professionals.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Taylor WJ, Grainger R (2012) Clinical features of gout. In: Terkeltaub R, ed. Gout and other crystal arthropathies, Firstth edn. Elsevier Saunders, Philadelphia PA Taylor WJ, Grainger R (2012) Clinical features of gout. In: Terkeltaub R, ed. Gout and other crystal arthropathies, Firstth edn. Elsevier Saunders, Philadelphia PA
3.
Zurück zum Zitat Taylor WJ (2013) Measurement of outcome in gout. Indian J Rheumatol 8:S11–S15CrossRef Taylor WJ (2013) Measurement of outcome in gout. Indian J Rheumatol 8:S11–S15CrossRef
4.
Zurück zum Zitat Alvarez_Hernandez E, Pelaez_Ballestas I, Vazquez_Mellado J et al (2008) Validation of the Health Assessment Questionnaire disability index in patients with gout. Arthritis Rheum 59:665–669CrossRefPubMed Alvarez_Hernandez E, Pelaez_Ballestas I, Vazquez_Mellado J et al (2008) Validation of the Health Assessment Questionnaire disability index in patients with gout. Arthritis Rheum 59:665–669CrossRefPubMed
5.
Zurück zum Zitat Taylor WJ, Colvine K, Gregory K, Collis J, McQueen FM, Dalbeth N (2008) The Health Assessment Questionnaire Disability Index is a valid measure of physical function in gout. Clin Exp Rheumatol 26:620–626PubMed Taylor WJ, Colvine K, Gregory K, Collis J, McQueen FM, Dalbeth N (2008) The Health Assessment Questionnaire Disability Index is a valid measure of physical function in gout. Clin Exp Rheumatol 26:620–626PubMed
6.
Zurück zum Zitat Colwell HH, Hunt BJ, Pasta DJ et al (2006) Gout Assessment Questionnaire: initial results of reliability, validity and responsiveness. Int J Clin Pract 60:1210–1217CrossRefPubMed Colwell HH, Hunt BJ, Pasta DJ et al (2006) Gout Assessment Questionnaire: initial results of reliability, validity and responsiveness. Int J Clin Pract 60:1210–1217CrossRefPubMed
7.
Zurück zum Zitat Singh JA, Taylor WJ, Simon LS et al (2011) Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol 38:1452–1457CrossRefPubMed Singh JA, Taylor WJ, Simon LS et al (2011) Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol 38:1452–1457CrossRefPubMed
8.
Zurück zum Zitat World Health Organisation (2002) Towards a common language for functioning, disability and health: ICF. World Health Organisation, Geneva World Health Organisation (2002) Towards a common language for functioning, disability and health: ICF. World Health Organisation, Geneva
9.
Zurück zum Zitat Coenen M, Cieza A, Stamm TA, Amann E, Kollerits B, Stucki G (2006) Validation of the International Classification of Functioning, Disability and Health (ICF) core set for rheumatoid arthritis from the patient perspective using focus groups. Arthritis Res Ther 8:R84CrossRefPubMedPubMedCentral Coenen M, Cieza A, Stamm TA, Amann E, Kollerits B, Stucki G (2006) Validation of the International Classification of Functioning, Disability and Health (ICF) core set for rheumatoid arthritis from the patient perspective using focus groups. Arthritis Res Ther 8:R84CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Cieza A, Stucki G, Weigl M, et al. ICF core sets for low back pain. J Rehabil Med 2004:69–74 Cieza A, Stucki G, Weigl M, et al. ICF core sets for low back pain. J Rehabil Med 2004:69–74
11.
Zurück zum Zitat Dreinhofer K, Stucki G, Ewert T, et al. ICF core sets for osteoarthritis. J Rehabil Med 2004:75–80 Dreinhofer K, Stucki G, Ewert T, et al. ICF core sets for osteoarthritis. J Rehabil Med 2004:75–80
12.
Zurück zum Zitat Boonen A, Braun J, van der Horst Bruinsma IE, et al. ASAS/WHO ICF core sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. Ann Rheum Dis;69:102–07 Boonen A, Braun J, van der Horst Bruinsma IE, et al. ASAS/WHO ICF core sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. Ann Rheum Dis;69:102–07
13.
Zurück zum Zitat Cieza A, Ewert T, Ustun TB, Chatterjee S, Kostanjsek N, Stucki G (2004) Development of ICF core sets for patients with chronic conditions. J Rehabil Med 44:9–11PubMed Cieza A, Ewert T, Ustun TB, Chatterjee S, Kostanjsek N, Stucki G (2004) Development of ICF core sets for patients with chronic conditions. J Rehabil Med 44:9–11PubMed
14.
Zurück zum Zitat Kiltz U, van der Heijde D, Boonen A et al (2015) Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis 74:830–835CrossRefPubMed Kiltz U, van der Heijde D, Boonen A et al (2015) Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis 74:830–835CrossRefPubMed
15.
Zurück zum Zitat Cieza A, Geyh S, Chatterji S, Kostanjsek N, Ustun B, Stucki G (2005) ICF linking rules: an update based on lessons learned. J Rehabil Med 37:212–218CrossRefPubMed Cieza A, Geyh S, Chatterji S, Kostanjsek N, Ustun B, Stucki G (2005) ICF linking rules: an update based on lessons learned. J Rehabil Med 37:212–218CrossRefPubMed
16.
Zurück zum Zitat Fitch K, Bernstein SJ, Aguilar MD et al (2001) The RAND/UCLA appropriateness method user’s manual. RAND, Santa Monica, CA Fitch K, Bernstein SJ, Aguilar MD et al (2001) The RAND/UCLA appropriateness method user’s manual. RAND, Santa Monica, CA
17.
Zurück zum Zitat Diaz_Torne C, Pou MA, Castellvi I, Corominas H, Taylor WJ (2014) Concerns of patients with gout are incompletely captured by OMERACT endorsed domains of measurement for chronic gout studies. J Clin Rheumatol 20:138–140CrossRefPubMed Diaz_Torne C, Pou MA, Castellvi I, Corominas H, Taylor WJ (2014) Concerns of patients with gout are incompletely captured by OMERACT endorsed domains of measurement for chronic gout studies. J Clin Rheumatol 20:138–140CrossRefPubMed
18.
Zurück zum Zitat Lindsay K, Gow P, Vanderpyl J, Logo P, Dalbeth N (2011) The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach. J Clin Rheumatol 17:1–6CrossRefPubMed Lindsay K, Gow P, Vanderpyl J, Logo P, Dalbeth N (2011) The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach. J Clin Rheumatol 17:1–6CrossRefPubMed
Metadaten
Titel
Discrepancies in how the impact of gout is assessed in outcomes research compared to how health professionals view the impact of gout, using the lens of the International Classification of Functioning, Health and Disability (ICF)
verfasst von
Eveline M. Kool
Marieke J. Nijsten
Annelies E. van Ede
Tim L. Jansen
William J. Taylor
Publikationsdatum
14.06.2016
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 9/2016
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3325-7

Weitere Artikel der Ausgabe 9/2016

Clinical Rheumatology 9/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.